ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Biocad and Hoffmann-La Roche side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BiocadHoffmann-La Roche
studies on the registry942,744
open to participants now12114
phase 3 studies under way1595
reach primary completion within a year476
programswith a study of their own in two years1080+25 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBiocadHoffmann-La Roche
Phase 1

Biocad: 2 of its 10 programs at phase 1

  1. BCD-256phase 1
  2. BCD-261phase 1
20%

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. AQUA07phase 1

and 28 more — sign in to see them all

41%
Phase 2

Biocad: 2 of its 10 programs at phase 2

  1. anti-TL1A monoclonal antibody, low dosephase 2
  2. BCD-236phase 2
20%

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%
Phase 3

Biocad: 6 of its 10 programs at phase 3

  1. divozilimabphase 3
  2. BCD-248phase 3
  3. pegdarbepoetin betaphase 3
  4. BCD-281phase 3
  5. Adalimumabphase 3

and 1 more — sign in to see them all

60%

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%
Approved, new studies00%

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Biocad1 readouts · 0 phase 3··

Biocad, Jan ’27: 1 program whose next study reaches primary completion

  1. anti-TL1A monoclonal antibody, low dosephase 2 · Jan 0 · NCT07080034
·········
Hoffmann-La Roche27 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 1 program whose next study reaches primary completion

  1. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289
  2. cevostamabphase 3 · Feb 26 · NCT05535244

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526

Hoffmann-La Roche, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. mosunetuzumabphase 3 · Oct 1 · NCT05207670
  2. emicizumabapproved, new study · Oct 6 · NCT06998524
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Biocad

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Hoffmann-La Roche

New programs 4

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 11

Where they overlap

Conditions where at least two of them have programs: 10 in all. A program counts in each condition its studies name most.

ConditionBiocadHoffmann-La Roche
Colitis, Ulcerativeboth · compare here

Biocad in Colitis, Ulcerative: 3 programs

  1. Adalimumabphase 3
  2. anti-TL1A monoclonal antibody, low dosephase 2
  3. BCD-261phase 1

Their studies: Biocad’s studies of Colitis, Ulcerative in search

Hoffmann-La Roche in Colitis, Ulcerative: 2 programs

  1. afimkibartphase 3
  2. RO7837195phase 2

Their studies: Hoffmann-La Roche’s studies of Colitis, Ulcerative in search

Multiple Myelomaboth · compare here

Biocad in Multiple Myeloma: 1 program

  1. BCD-248phase 3

Their studies: Biocad’s studies of Multiple Myeloma in search

Hoffmann-La Roche in Multiple Myeloma: 4 programs

  1. cevostamabphase 3
  2. hyaluronidase (human recombinant)phase 2
  3. RO7851624phase 1
  4. RO7875913phase 1

Their studies: Hoffmann-La Roche’s studies of Multiple Myeloma in search

Multiple Sclerosisboth · compare here

Biocad in Multiple Sclerosis: 1 program

  1. divozilimabphase 3

Their studies: Biocad’s studies of Multiple Sclerosis in search

Hoffmann-La Roche in Multiple Sclerosis: 4 programs

  1. fenebrutinibphase 3
  2. P-CD19CD20-ALLO1 Cellsphase 1
  3. RO7845860phase 1
  4. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Multiple Sclerosis in search

Arthritis, Rheumatoidboth · compare here

Biocad in Arthritis, Rheumatoid: 1 program

  1. Adalimumabphase 3

Their studies: Biocad’s studies of Arthritis, Rheumatoid in search

Hoffmann-La Roche in Arthritis, Rheumatoid: 3 programs

  1. afimkibartphase 3
  2. fenebrutinibphase 3
  3. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Arthritis, Rheumatoid in search

Crohn Diseaseboth · compare here

Biocad in Crohn Disease: 2 programs

  1. Adalimumabphase 3
  2. anti-TL1A monoclonal antibody, low dosephase 2

Their studies: Biocad’s studies of Crohn Disease in search

Hoffmann-La Roche in Crohn Disease: 1 program

  1. afimkibartphase 3

Their studies: Hoffmann-La Roche’s studies of Crohn Disease in search

Hemoglobinuria, Paroxysmalboth · compare here

Biocad in Hemoglobinuria, Paroxysmal: 1 program

  1. eculizumabphase 3

Their studies: Biocad’s studies of Hemoglobinuria, Paroxysmal in search

Hoffmann-La Roche in Hemoglobinuria, Paroxysmal: 2 programs

  1. Crovalimabphase 3
  2. pegcetacoplanphase 1

Their studies: Hoffmann-La Roche’s studies of Hemoglobinuria, Paroxysmal in search

Atypical Hemolytic Uremic Syndromeboth · compare here

Biocad in Atypical Hemolytic Uremic Syndrome: 1 program

  1. eculizumabphase 3

Their studies: Biocad’s studies of Atypical Hemolytic Uremic Syndrome in search

Hoffmann-La Roche in Atypical Hemolytic Uremic Syndrome: 1 program

  1. Crovalimabphase 3

Their studies: Hoffmann-La Roche’s studies of Atypical Hemolytic Uremic Syndrome in search

Guillain-Barre Syndromeboth · compare here

Biocad in Guillain-Barre Syndrome: 1 program

  1. eculizumabphase 3

Their studies: Biocad’s studies of Guillain-Barre Syndrome in search

Hoffmann-La Roche in Guillain-Barre Syndrome: 1 program

  1. Crovalimabphase 3

Their studies: Hoffmann-La Roche’s studies of Guillain-Barre Syndrome in search

Multiple Sclerosis, Relapsing-Remittingboth · compare here

Biocad in Multiple Sclerosis, Relapsing-Remitting: 1 program

  1. BCD-281phase 3

Their studies: Biocad’s studies of Multiple Sclerosis, Relapsing-Remitting in search

Hoffmann-La Roche in Multiple Sclerosis, Relapsing-Remitting: 1 program

  1. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Multiple Sclerosis, Relapsing-Remitting in search

Myasthenia Gravisboth · compare here

Biocad in Myasthenia Gravis: 1 program

  1. eculizumabphase 3

Their studies: Biocad’s studies of Myasthenia Gravis in search

Hoffmann-La Roche in Myasthenia Gravis: 1 program

  1. hyaluronidase (human recombinant)phase 2

Their studies: Hoffmann-La Roche’s studies of Myasthenia Gravis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetBiocadHoffmann-La Roche
C5eculizumabruleCrovalimabrule
A target, or a pathogen for a vaccine, known for: Biocad 2 of 10 · Hoffmann-La Roche 39 of 80 programs (21 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Hoffmann-La Roche: 25).